Genome Editing– tag –
-
Epicrispr Raises $90M to Advance Epigenetic Editing Drug EPI-321 for Rare Muscle Disease FSHD, Completes Phase 1 Enrollment
BioPharma Dive USA Overview Epicrispr Biotechnologies has successfully raised $90 million in Series C financing to accelerate the development of EPI-321, an epigenetic editing drug for facioscapulohumeral muscular dystrophy (FSHD). EPI-3... -
Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity: Diverse Modalities Pioneer New Treatment Avenues
PMC - NIH USA Overview Clinical development of engineered cellular immunotherapies for autoimmune diseases is rapidly advancing, poised to offer novel therapeutic options. Diverse modalities, including CAR-T cells, CAR-NK cells, and TCR-... -
Epigenome Editing of Human Hematopoietic Stem Cells Achieves Sustained and Reversible Thrombosis Prevention
preLights (The Company of Biologists) Unknown Overview A groundbreaking study demonstrated that epigenome editing of human hematopoietic stem cells (HSCs) enables sustained and reversible thrombosis prevention. This innovative technology... -
Texas Children’s Hospital Establishes Cell and Gene Therapy Innovation Hub to Accelerate Development and Expand Access
Texas Children's Hospital USA Overview Texas Children's Hospital has established a new innovation hub to accelerate breakthroughs in cell and gene therapy (CGT). This comprehensive facility centralizes all necessary resources and experti... -
Children’s Hospital Los Angeles Joins Multi-Center Trial for In Vivo CRISPR Gene Editing Therapy for Sickle Cell Disease
Children's Hospital Los Angeles (CHLA) Facebook USA Overview Children's Hospital Los Angeles (CHLA) has announced its participation in a multi-center clinical trial evaluating a novel CRISPR-based, direct gene editing therapy for sickle ... -
CRISPR and the Dawn of Germline Editing: Curing Hereditary Disease at the Source
Liv Hospital Turkey Overview Germline genome editing, often referred to as 'baby gene editing,' leverages advanced CRISPR technology to offer a potentially curative approach for monogenic diseases at the embryonic stage. While CRISPR's e... -
CRISPR Gene Editing Achieves Clinical Breakthroughs in Sickle Cell Disease Treatment
Liv Hospital Turkey Overview Clinical trials employing CRISPR gene-editing technology for sickle cell disease are reporting highly promising results, significantly reducing severe vaso-occlusive crises and transfusion dependency. Utilizi... -
Investigational CRISPR Therapy Achieves First Clinical Success in Patient with Drug-Resistant E. Coli, Curing Infection
Clinical Trials Arena Unknown Overview A groundbreaking clinical trial has reported the first successful treatment of a patient with multidrug-resistant E. coli using a CRISPR-based therapy. This innovative treatment directly targeted an... -
CRISPR Cancer Therapy 2026: 32 Clinical Trials Underway, Gene-Edited T-Cells Face Efficacy and Off-Target Challenges
Hirschfeld Oncology USA Overview As of 2026, 32 clinical trials are investigating CRISPR-edited immunotherapies for cancer, predominantly focusing on ex vivo gene-edited immune cells. While these therapies generally demonstrate favorable... -
University of Wisconsin-Madison Researchers Develop Platform to Identify Host Genes Hindering CRISPR Editing Efficiency, Paving Way for Enhanced Gene Therapy Efficacy
News-Medical.Net USA Overview A research team at the University of Wisconsin-Madison has developed an innovative platform to systematically identify specific host genes that impede the efficiency of CRISPR gene editing. This study provid...
